Nifedipine (Tocolytic) — Discount Pricing

Other medications in Women's Health

• Norethindrone-Ethinyl Estradiol
• Oxytocin
• Progesterone Vaginal
• Relugolix
• Terbutaline
• Betamethasone Prenatal
• Carboprost
• Clomiphene Citrate

What Nifedipine (Tocolytic) is approved for (FDA label)

I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied.

Source: Read the full FDA label on DailyMed. Label effective date: August 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Nifedipine (Tocolytic) (FDA label)

ADVERSE EXPERIENCES Over 1000 patients from both controlled and open trials with nifedipine extended-release tablets in hypertension and angina were included in the evaluation of adverse experiences. All side effects reported during nifedipine extended-release tablets therapy were tabulated independent of their causal relation to medication. The most common side effect reported with nifedipine extended-release tablets was edema which was dose related and ranged in frequency from approximately 10% to about 30% at the highest dose studied (180 mg). Other common adverse experiences reported in placebo-controlled trials include: Of these, only edema and headache were more common in nifedipine extended-release tablets patients than placebo patients.

Source: FDA prescribing information (DailyMed). Set ID: 4ee466dc-5a4e-4c77-8e94-8b510cafd61b. SPL document ID: d2a3cbad-62f3-4db1-96c4-da28631477a0. Label effective date: August 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Nifedipine (Tocolytic) (FDA label)

Known hypersensitivity reaction to nifedipine.

Source: FDA prescribing information (DailyMed). Set ID: 4ee466dc-5a4e-4c77-8e94-8b510cafd61b. SPL document ID: d2a3cbad-62f3-4db1-96c4-da28631477a0. Label effective date: August 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Nifedipine (Tocolytic) (FDA label)

Beta-adrenergic blocking agents: (see and .) Experience in over 1400 patients with nifedipine capsules in a noncomparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension, or exacerbation of angina. Long-acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination. Digitalis: Administration of nifedipine with digoxin increased digoxin levels in nine of twelve normal volunteers. The average increase was 45%. Another investigator found no increase in digoxin levels in thirteen patients with coronary artery disease. In an uncontrolled study of over two hundred patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed.

Source: FDA prescribing information (DailyMed). Set ID: 4ee466dc-5a4e-4c77-8e94-8b510cafd61b. SPL document ID: d2a3cbad-62f3-4db1-96c4-da28631477a0. Label effective date: August 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.